ArticleAnnals of translational medicine2023

Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study.

Yulan Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.